• Fri. Apr 19th, 2024

Lara Goldstein

  • Home
  • Canadian At-Home Microdose Psilocybin Clinical Trial Finalized, Here Are The Details

Canadian At-Home Microdose Psilocybin Clinical Trial Finalized, Here Are The Details

[ad_1] Biopharma company Apex Labs Ltd. has completed one of the first take-home microdose psilocybin clinical trials, meeting all study endpoints over a two-month period with no adverse events reported.…

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More – Filament Health (OTC:FLHLF), AdvisorShares Psychedelics ETF (ARCA:PSIL), Field Trip Health (OTC:FTHWF), FSD Pharma (NASDAQ:HUGE), Reunion Neuroscience (NASDAQ:REUN), Lucy Scientific Discovery (NASDAQ:LSDI), Delic Hldgs (OTC:DELCF), ETF Series Solutions PSYK ETF (ARCA:PSYK), Incannex Healthcare (NASDAQ:IXHL), Red Light Holland (OTC:TRUFF), Compass Pathways (NASDAQ:CMPS), Enveric Biosciences (NASDAQ:ENVB), Braxia Scientific (OTC:BRAXF), Mindset Pharma (OTC:MSSTF), Irwin Naturals (OTC:IWINF), Clearmind Medicine (NASDAQ:CMND), SILO Pharma (NASDAQ:SILO)

[ad_1] Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered In the first months of 2023, state-level psychedelics policy reform has been so constant that…

NYC’s Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility – Awakn Life Sciences (OTC:AWKNF)

[ad_1] In light of the latest news regarding the DEA’s telehealth regulations and the closing of two renowned ketamine clinics with facilities in the U.S., Benzinga had the opportunity to interview Jay Godfrey, co-founder of the NYC-based…

Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal – Braxia Scientific (OTC:BRAXF), Irwin Naturals (OTC:IWINF)

[ad_1] Irwin Naturals Inc. IWINF has terminated the non-binding amended and restated letter of intent (LOI) for a business combination with medical research and telemedicine company Braxia Scientific Corp. BRAXF.…

Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock – FSD Pharma (NASDAQ:HUGE)

[ad_1] FSD Pharma Inc. HUGE has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing investigations related to suspected naked short selling of the…

COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression – Compass Pathways (NASDAQ:CMPS)

[ad_1] COMPASS Pathways’ CMPS Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as newly published data demonstrate…

Enveric Biosciences: Novel Next-Gen Drug Discovery Platform Includes Rare Toad Enzyme – Enveric Biosciences (NASDAQ:ENVB)

[ad_1] Biopharma company Enveric Biosciences ENVB has shared new findings involving the first-ever isolation of a specific enzyme from the cane toad, plus the successful development of a bioproduction platform…

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

[ad_1] In the first months of 2023, state-level psychedelics policy reform has been so constant that it is hard to view it as a passing trend. While the first reported legalization proposal was…

Deepak Chopra’s Wellness Businesses Form Partnership With The Healing Company – Healing Co (OTC:HLCO)

[ad_1] The Healing Company HLCO and renowned integrative medicine specialist Dr. Deepak Chopra, MD. have become partners following a deal through which the company will acquire Chopra Global’s well-being experiences businesses. …

Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License – Wellbeing Digital (OTC:KONEF)

[ad_1] A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc. KONEF, KGK Science’s application for a Controlled Drugs And Substances (CDS) dealers license with Health…

Bipartisan Lawmakers Introduce Rescheduling Bill To Enable Psychedelics Research

[ad_1] Senators Cory Booker (D-NJ), Rand Paul (R-KY) Reps Madeleine Dean (D-PA) and Nancy Mace (R-SC) filed a revised bill requesting an update on the federal scheduling of “breakthrough therapies” -an FDA…

Who’s Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person

[ad_1] This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our…

Benzinga’s Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners

[ad_1] The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space.  From companies that perform advanced clinical research…

Benzinga’s Psychedelics Capital Conference Is Open For Business: Meet Our Renowned Keynote Speaker

[ad_1] This year is the second edition of what is rapidly becoming the place to be for those interested in or already involved in the psychedelics space: new deals get closed, money gets…

Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla – Mindset Pharma (OTC:MSSTF), Optimi Health (OTC:OPTHF)

[ad_1] The exclusive sales partnership between psychedelics biotechs Mindset Pharma MSSTF and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. The psilocybin batch was purchased by…

Cybin: Positive Clinical Trial On Psilocybin Analog For Major Depression & Updates On DMT Analog Program – Cybin (AMEX:CYBN)

[ad_1] Psychedelics biotech company Cybin Inc. CYBN shared progress updates for its two lead clinical development programs: proprietary deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD)…

Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program – Algernon Pharmaceuticals (OTC:AGNPF)

[ad_1] Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. AGNPF will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.  Effective as of market opening…

Lucy Scientific Secures First Delivery Of Psilocybin To Israel Following DMT & 5-MeO-DMT – Lucy Scientific Discovery (NASDAQ:LSDI)

[ad_1] Lucy Scientific Discovery Inc. LSDI, a Canada-based psychedelics manufacturing company, has inked its first commercial sale to the prestigious Hadassah BrainLabs, also known as the Center for Psychedelics Research at…

Psyched: Hawaii And Minnesota’s Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry’s Future And More – Filament Health (OTC:FLHLF)

[ad_1] Two Bills Approved By Hawaii Senators With Governor’s Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of…

Transcend Therapeutics Raises $40M In Series A Round Led By Alpha Wave Global And Integrated VC

[ad_1] Transcend Therapeutics closed a Series A funding round of $40 million with leading support from Alpha Wave Global and Integrated Investment Partners.  Founded in 2021 and incubated by leading…

Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind – Pharmadrug (OTC:LMLLF), PharmaTher Holdings (OTC:PHRRF)

[ad_1] Specialty R&D psychedelics company PharmaDrug Inc. LMLLF has inked a research collaboration agreement with PharmaTher Holdings Ltd. PHRRF to evaluate the delivery of DMT through PharmaTher’s microneedle patch technology. PharmaDrug…

2C-B Vs. Psilocybin: New Study Shares Insightful Trial Results On The Mescaline-Derived Psychedelic’s Effects

[ad_1] A new clinical trial assessed the immediate acute effects of 2C-B hallucinogenic phenethylamine compared to psilocybin on subjective experience, mood and cognition. The study, conducted by Netherlands’ University of…

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More – Filament Health (OTC:FLHLF), AdvisorShares Psychedelics ETF (ARCA:PSIL), Reunion Neuroscience (NASDAQ:REUN), Algernon Pharmaceuticals (OTC:AGNPF), Wellbeing Digital (OTC:KONEF), Nova Mentis Life Science (OTC:NMLSF), ETF Series Solutions PSYK ETF (ARCA:PSYK), Awakn Life Sciences (OTC:AWKNF), Numinus Wellness (OTC:NUMIF), Red Light Holland (OTC:TRUFF), Cybin (AMEX:CYBN), Irwin Naturals (OTC:IWINF), Small Pharma (OTC:DMTTF)

[ad_1] Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington’s Green Lights, New Hampshire’s Setback Earlier this week, three bills were introduced and added to…

Delix: Elucidating How Psychedelics Actually Induce Neuroplasticity Vs. SSRIs

[ad_1] Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways.  The paper, developed in collaboration…

Psychedelics States Reform: Utah, Iowa and Missouri’s New Bills, Hawaii And Arizona’s Green Lights, New Hampshire’s Setback

[ad_1] Newly introduced bills are added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get…